CN117545771A - 细胞免疫治疗的应用 - Google Patents

细胞免疫治疗的应用 Download PDF

Info

Publication number
CN117545771A
CN117545771A CN202280022826.0A CN202280022826A CN117545771A CN 117545771 A CN117545771 A CN 117545771A CN 202280022826 A CN202280022826 A CN 202280022826A CN 117545771 A CN117545771 A CN 117545771A
Authority
CN
China
Prior art keywords
cells
seq
cell
patient
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280022826.0A
Other languages
English (en)
Chinese (zh)
Inventor
李宗海
汪薇
肖珺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clegg Medical Co ltd
Original Assignee
Clegg Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clegg Medical Co ltd filed Critical Clegg Medical Co ltd
Publication of CN117545771A publication Critical patent/CN117545771A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/51—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/52—Intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202280022826.0A 2021-04-08 2022-04-08 细胞免疫治疗的应用 Pending CN117545771A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021103775187 2021-04-08
CN202110377518 2021-04-08
PCT/CN2022/085921 WO2022214089A1 (zh) 2021-04-08 2022-04-08 细胞免疫治疗的应用

Publications (1)

Publication Number Publication Date
CN117545771A true CN117545771A (zh) 2024-02-09

Family

ID=83545188

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280022826.0A Pending CN117545771A (zh) 2021-04-08 2022-04-08 细胞免疫治疗的应用

Country Status (5)

Country Link
US (1) US20240181055A1 (cg-RX-API-DMAC7.html)
EP (1) EP4321533A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024527180A (cg-RX-API-DMAC7.html)
CN (1) CN117545771A (cg-RX-API-DMAC7.html)
WO (1) WO2022214089A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117430707B (zh) * 2023-10-25 2024-04-19 重庆天科雅生物科技有限公司 一种cik细胞的制备方法及其在治疗癌症中的用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
CN104087607B (zh) 2013-04-01 2017-06-20 科济生物医药(上海)有限公司 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞
CN104140974B (zh) 2013-05-08 2017-09-29 科济生物医药(上海)有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
JP6682509B2 (ja) 2014-05-14 2020-04-15 カースゲン セラピューティクス リミテッドCarsgen Therapeutics Limited キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するtリンパ球
CN105194661B (zh) 2014-06-26 2019-05-03 科济生物医药(上海)有限公司 时空可调性抑制病理性靶细胞的系统
CN120329449A (zh) 2014-07-17 2025-07-18 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
US10093746B2 (en) 2014-09-04 2018-10-09 The Trustees Of The University Of Pennsylvania Glypican-3 antibody and uses thereof
ES2851123T1 (es) 2014-09-26 2021-09-03 Baylor College Medicine Receptores quiméricos de antígeno específicos de glipicano-3 para inmunoterapia adoptiva
CN105713881B (zh) 2014-12-04 2019-12-06 科济生物医药(上海)有限公司 双靶向gpc3和asgpr1的转基因免疫效应细胞及其应用
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
CN106146666B (zh) 2015-03-26 2019-09-06 科济生物医药(上海)有限公司 靶向cldn6的免疫效应细胞及其制备方法和应用
AU2016304060B2 (en) 2015-08-03 2022-09-29 Crage Medical Co., Limited Antibody against glypican-3 and application thereof
CN106467573B (zh) 2015-08-21 2021-05-25 佧珐药业有限公司 抗间皮素全人抗体以及靶向间皮素的免疫效应细胞
CN106519037B (zh) 2015-09-11 2019-07-23 科济生物医药(上海)有限公司 可活化的嵌合受体
CN109824778B (zh) 2015-09-18 2022-07-19 上海科济制药有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
CN105331585A (zh) 2015-11-13 2016-02-17 科济生物医药(上海)有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
CN109414512A (zh) * 2016-04-22 2019-03-01 科济生物医药(上海)有限公司 用于细胞免疫疗法的组合物和方法
CN118165113B (zh) 2016-04-26 2025-10-28 恺兴生命科技(上海)有限公司 一种改善免疫应答细胞功能的方法
WO2018006882A1 (zh) 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用
US11427633B2 (en) 2016-12-13 2022-08-30 Crage Medical Co., Limited Anti-CD19 humanized antibody and immune effector cell targeting cd 19
EP3572427B1 (en) 2017-01-23 2025-06-25 CRAGE medical Co., Limited Bcma-targeting antibody and use thereof
CN108456250B (zh) 2017-02-17 2025-11-28 恺兴生命科技(上海)有限公司 靶向il-13ra2的抗体及其应用
WO2018149358A1 (zh) 2017-02-17 2018-08-23 科济生物医药(上海)有限公司 靶向il-13ra2的抗体及其应用
EP3585817A4 (en) * 2017-02-22 2020-12-02 Aleta Biotherapeutics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
CN108853144A (zh) 2017-05-16 2018-11-23 科济生物医药(上海)有限公司 Toll样受体激动剂与免疫效应细胞的联用
CN108866003A (zh) 2017-05-16 2018-11-23 科济生物医药(上海)有限公司 基因工程化的细胞及应用
KR102412805B1 (ko) 2017-05-31 2022-06-27 크라제 메디컬 씨오 리미티드 세포 면역 요법을 위한 조성물 및 방법
CN109385403B (zh) 2017-08-04 2024-03-08 恺兴生命科技(上海)有限公司 靶向gpc3的car nk细胞
CN109385400A (zh) 2017-08-09 2019-02-26 科济生物医药(上海)有限公司 共表达pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
CN109468279A (zh) 2017-09-08 2019-03-15 科济生物医药(上海)有限公司 靶向gpc3的免疫效应细胞及其应用
WO2019047932A1 (zh) 2017-09-08 2019-03-14 科济生物医药(上海)有限公司 基因工程化的t细胞及应用
CN109503715B (zh) 2017-09-15 2023-12-15 科济生物医药(上海)有限公司 Il-4r的融合蛋白及其应用
CN109796532B (zh) 2017-11-17 2024-09-10 恺兴生命科技(上海)有限公司 靶向成纤维激活蛋白α的结合单元及其应用
CN109880803B (zh) 2017-12-06 2024-06-07 恺兴生命科技(上海)有限公司 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用
CN110055275A (zh) 2018-01-19 2019-07-26 科济生物医药(上海)有限公司 一种质粒载体对、其修饰的免疫细胞及其应用
JP2021512875A (ja) 2018-02-02 2021-05-20 カースゲン セラピューティクス カンパニー リミテッドCarsgen Therapeutics Co., Ltd. 細胞免疫療法の組み合わせ
US12186343B2 (en) 2018-03-09 2025-01-07 Crage Medical Co., Limited Method and composition for treating tumors
EP3765094A4 (en) * 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
US20220127570A1 (en) 2018-05-03 2022-04-28 Cafa Therapeutics Limited Immune effector cell and use thereof
CN110438082B (zh) 2018-05-04 2024-03-08 恺兴生命科技(上海)有限公司 表达il-21r结合蛋白的免疫效应细胞
CN110468105B (zh) 2018-05-09 2024-03-22 恺兴生命科技(上海)有限公司 表达il-18r结合蛋白的免疫效应细胞
JP2021523743A (ja) 2018-05-15 2021-09-09 カースゲン セラピューティクス カンパニー リミテッドCarsgen Therapeutics Co., Ltd. 遺伝子操作された細胞及びその応用
CN112930199B (zh) 2018-07-24 2024-08-13 恺兴生命科技(上海)有限公司 免疫效应细胞治疗肿瘤的方法
CN112771167B (zh) 2018-09-20 2025-09-26 克莱格医学有限公司 表达有趋化因子的细胞及用途
AU2019341365A1 (en) 2018-09-21 2021-05-27 Crage Medical Co., Limited Method for gene editing of cell on the basis of CRISPR/Cas system
US20210347851A1 (en) * 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
US12534532B2 (en) 2018-10-26 2026-01-27 Crage Medical Co., Limited CLL1-targeting antibody and application thereof
EP3892333A4 (en) 2018-12-07 2022-11-30 CRAGE medical Co., Limited ANTI-TUMOR POLYIMMUNOTHERAPY
JP2022512450A (ja) 2018-12-13 2022-02-03 カースゲン セラピューティクス カンパニー リミテッド Gpc3を標的とする免疫エフェクター細胞およびその応用
KR20210126008A (ko) 2019-01-07 2021-10-19 카르스젠 테라퓨틱스 컴퍼니, 리미티드 세포 면역 치료의 조합
JP2022523749A (ja) 2019-02-01 2022-04-26 クレージュ メディカル カンパニー,リミテッド Tcr融合タンパク質およびtcr融合タンパク質を発現する細胞
US20220325241A1 (en) 2019-08-09 2022-10-13 Crage Medical Co., Limited Immune effector cell for co-expressing chemokine receptor
CN114867490A (zh) 2019-09-20 2022-08-05 克莱格医学有限公司 细胞因子调控表达的免疫效应细胞
WO2021057906A1 (zh) 2019-09-25 2021-04-01 科济生物医药(上海)有限公司 表达il-15的免疫效应细胞
AU2021204861B2 (en) 2020-01-03 2024-10-17 Crage Medical Co., Limited Anti-claudin 18.2 antibody and use thereof
CN115003818A (zh) 2020-01-22 2022-09-02 科济生物医药(上海)有限公司 病毒载体转导细胞的方法
KR20230012571A (ko) 2020-05-18 2023-01-26 크라제 메디컬 씨오 리미티드 면역 이펙터 세포를 이용한 종양 치료
CN112062864A (zh) * 2020-09-18 2020-12-11 樊克兴 靶向bcma肿瘤抗原受体修饰t细胞的制备方法和应用

Also Published As

Publication number Publication date
WO2022214089A1 (zh) 2022-10-13
JP2024527180A (ja) 2024-07-22
EP4321533A4 (en) 2025-05-07
US20240181055A1 (en) 2024-06-06
EP4321533A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
CN113286811B (zh) 改善过继性细胞疗法的效力和安全性
EP3914611B1 (en) Receptors providing targeted costimulation for adoptive cell therapy
ES2941370T3 (es) Control de la toxicidad para la actividad antitumoral de los CAR
US20250177544A1 (en) Method and composition for treating tumors
KR20200099132A (ko) 조작된 세포의 치료적 조성물을 생성하기 위한 프로세스
KR20200133370A (ko) 입양 주입된 t 세포의 지속성 강화 방법
KR20230016183A (ko) 키메라 항원 수용체를 발현하는 바이러스 특이적 면역 세포
KR20190101979A (ko) 합성 면역 수용체 및 이의 사용 방법
BR112019022893A2 (pt) combinação de uma terapia celular e um composto imunomodulatório
CN108137670A (zh) Ny-eso-1特异性tcr及其使用方法
WO2017219934A1 (zh) 一种高效稳定表达抗体的杀伤性细胞及其用途
JP2023534808A (ja) 養子細胞療法のための標的共刺激を提供する受容体
KR20190026740A (ko) 입양 세포 치료법을 이용한 b 세포 악성종양의 치료 방법
CN114616337A (zh) 嵌合CD3融合蛋白与基于anti-CD3的双特异性T细胞激活元件的联合表达
US20230227576A1 (en) Receptors providing targeted costimulation for adoptive cell therapy
CN114206357A (zh) 使用融合蛋白进行tcr重编程的组合物和方法
CN116209461A (zh) Cd-30阳性癌症的治疗
CN116286665A (zh) 嵌合抗原受体细胞分泌治疗剂
US20240058447A1 (en) Use of fusion constructs for il-2 independent t cell therapy
EP4321533A1 (en) Cellular immunotherapy use
WO2022033483A1 (zh) 多功能的免疫效应细胞及其应用
WO2022268162A1 (zh) 治疗肿瘤的方法和组合物
WO2024243429A2 (en) Use of fusion constructs for cd4+ t cell therapy
WO2024243428A2 (en) Use of fusion constructs for cell therapy
Van den Eynde O16 Immunoscore® Colon analytical performance

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination